PTD-DBM + Valproic Acid
Synthetic peptide studied in animal and cell models for wnt/beta-catenin pathway reactivation and dermal papilla inductivity restoration
Last updated: March 1, 2026
- Compound
- PTD-DBM + Valproic Acid
- Class
- Recovery peptide
- Summary
- Synthetic peptide studied in animal and cell models for wnt/beta-catenin pathway reactivation, dermal papilla inductivity restoration, hair follicle cycling modulation.
- Mechanism
- Hair Follicle Gene Activation & DP Inductivity Restoration
- Research Status
- Preclinical
- Routes Studied
- Topical application
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About PTD-DBM + Valproic Acid?
- What is PTD-DBM + Valproic Acid?
- PTD-DBM + Valproic Acid is a synthetic peptide studied in animal and cell models for wnt/beta-catenin pathway reactivation and dermal papilla inductivity restoration.
- Is PTD-DBM + Valproic Acid clinically proven?
- No. Human evidence remains limited and does not establish PTD-DBM + Valproic Acid as clinically proven.
- What has PTD-DBM + Valproic Acid been studied for?
- PTD-DBM + Valproic Acid has been studied in preclinical models of wnt/beta-catenin pathway reactivation, dermal papilla inductivity restoration, hair follicle cycling modulation. These findings have not been confirmed in large-scale human trials.
- Is PTD-DBM + Valproic Acid approved?
- No. PTD-DBM + Valproic Acid is not an approved drug and remains a research compound.
What Is PTD-DBM + Valproic Acid?
PTD-DBM (Protein Transduction Domain-Dishevelled Binding Motif) combined with Valproic Acid represents an innovative topical approach to hair follicle regeneration research. This combination targets two complementary nodes of the Wnt/beta-catenin signaling pathway, the master regulator of hair follicle morphogenesis, cycling, and neogenesis. The PTD-DBM peptide was developed by researchers at Yonsei University College of Medicine in South Korea, whose work published in the Journal of Investigative Dermatology demonstrated that this combination...
Evidence Summary
PTD-DBM + Valproic Acid has preliminary preclinical evidence only. Human clinical trial data is not available.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Wnt/Beta-Catenin Pathway Reactivation | Animal studies |
| Dermal Papilla Inductivity Restoration | Animal studies |
| Hair Follicle Cycling Modulation | Animal studies |
| Targeted Topical Delivery | Animal studies |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
PTD-DBM + Valproic Acid is best understood as a preclinical research compound with promising biological signals but limited human validation. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for PTD-DBM + Valproic Acid is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has PTD-DBM + Valproic Acid Been Studied For?
Research areas where PTD-DBM + Valproic Acid has been investigated in published studies
-
Wnt/Beta-Catenin Pathway Reactivation PTD-DBM + Valproic Acid has been studied in animal models of wnt/beta-catenin pathway reactivation. These findings have not been confirmed in controlled human trials.
-
Dermal Papilla Inductivity Restoration PTD-DBM + Valproic Acid has been studied in animal models of dermal papilla inductivity restoration. These findings have not been confirmed in controlled human trials.
-
Hair Follicle Cycling Modulation PTD-DBM + Valproic Acid has been studied in animal models of hair follicle cycling modulation. These findings have not been confirmed in controlled human trials.
-
Targeted Topical Delivery PTD-DBM + Valproic Acid has been studied in animal models of targeted topical delivery. These findings have not been confirmed in controlled human trials.
How Does PTD-DBM + Valproic Acid Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 PTD-Mediated Cell Penetration
- 02 Dishevelled Protein Activation by DBM
- 03 GSK-3beta Inhibition by Valproic Acid
- 04 Beta-Catenin Nuclear Accumulation
Not sure if PTD-DBM + Valproic Acid is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about PTD-DBM + Valproic Acid.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate PTD-DBM + Valproic Acid
How Is PTD-DBM + Valproic Acid Administered?
PTD-DBM + Valproic Acid is available via Topical application. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of PTD-DBM + Valproic Acid?
What Conditions Has PTD-DBM + Valproic Acid Been Linked To?
Have Questions About PTD-DBM + Valproic Acid?
Published studies on PTD-DBM + Valproic Acid can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
PTD-DBM + Valproic Acid is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
A qualified specialist experienced with peptide therapies can help you understand the current evidence and determine suitability.
Ready to discuss PTD-DBM + Valproic Acid with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026